U.S. Markets close in 1 hr 59 mins
  • S&P 500

    4,439.27
    -43.46 (-0.97%)
     
  • Dow 30

    34,526.09
    -189.30 (-0.55%)
     
  • Nasdaq

    13,945.97
    -208.05 (-1.47%)
     
  • Russell 2000

    2,015.16
    -8.87 (-0.44%)
     
  • Crude Oil

    84.94
    -0.61 (-0.71%)
     
  • Gold

    1,832.40
    -10.20 (-0.55%)
     
  • Silver

    24.38
    -0.34 (-1.38%)
     
  • EUR/USD

    1.1351
    +0.0033 (+0.2951%)
     
  • 10-Yr Bond

    1.7560
    -0.0770 (-4.20%)
     
  • Vix

    27.27
    +1.68 (+6.57%)
     
  • GBP/USD

    1.3559
    -0.0041 (-0.2997%)
     
  • USD/JPY

    113.6880
    -0.4120 (-0.3611%)
     
  • BTC-USD

    38,422.50
    -4,638.39 (-10.77%)
     
  • CMC Crypto 200

    903.29
    +660.61 (+272.22%)
     
  • FTSE 100

    7,494.13
    -90.88 (-1.20%)
     
  • Nikkei 225

    27,522.26
    -250.64 (-0.90%)
     

TRACON Pharmaceuticals to Present at the Jefferies London Virtual Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • TCON

SAN DIEGO, Nov. 11, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Jefferies London Virtual Healthcare Conference, being held November 18-19, 2021.

The fireside chat will be available on-demand beginning at 3:00 AM Eastern Time on Thursday, November 18, 2021, in the Investors section on the Company’s website at www.traconpharma.com.

About TRACON

TRACON develops targeted therapies for cancer utilizing a capital efficient, CRO independent, product development platform. The Company’s clinical-stage pipeline includes: Envafolimab, a PD-L1 single-domain antibody given by rapid subcutaneous injection that is being studied in the pivotal ENVASARC trial for sarcoma; YH001, a potential best-in-class CTLA-4 antibody in Phase 1 development; TRC102, a Phase 2 small molecule drug candidate for the treatment of lung cancer; and TJ004309, a CD73 antibody in Phase 1 development for the treatment of advanced solid tumors. TRACON is actively seeking additional corporate partnerships whereby it leads U.S. regulatory and clinical development and shares in the cost and risk of clinical development and leads U.S. commercialization. In these partnerships TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the U.S. To learn more about TRACON and its product pipeline, visit TRACON's website at www.traconpharma.com.

Company Contact:

Investor Contact:

Mark Wiggins

Brian Ritchie

Chief Business Officer

LifeSci Advisors LLC

(858) 251-3492

(212) 915-2578

mwiggins@traconpharma.com

britchie@lifesciadvisors.com